Abstract
In this issue of Cancer Cell, Topp et al. analyze data from 799 patients treated with pembrolizumab beyond progression by RECIST 1.1 across six trials......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
